Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

Inclusion Criteria: * Non-immuno compromised male or female aged 8 years and older * Clinical diagnosis of mild to moderate Atopic Dermatitis (AD) * Failed to respond adequately to other topical prescription treatments for AD, or for whom those treatments are not advisable. * A diagnosis of AD for at least 3 months * An Investigator's Global Assessment (IGA) of disease severity of mild or moderate at baseline (score of 2 or 3) * Affected area of AD involvement at least 5% body surface area (BSA) * Treated with a bland emollient for at least 7 days Exclusion Criteria: * Females who are pregnant, breast feeding, or who wish to become pregnant during the study period * Active cutaneous bacterial or viral infection in any treatment area at baseline (e.g., clinically infected atopic dermatitis, impetigo). * Sunburn, extensive scarring or pigmented lesion(s) in any treatment area at baseline, which would interfere with evaluations * History or presence of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, ichthyosis, or scabies. * History or presence of Netherton's Syndrome, immunological deficiencies or diseases, HIV, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders * Concurrent disease or treatment likely to interfere with the study treatment or evaluations * Known allergy or hypersensitivity to pimecrolimus or any other component of the drug products * Not willing to minimize or avoid natural and artificial sunlight exposure during treatment